Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Open access
Herrera, Alex F., Mei, Matthew, Low, Lawrence, Kim, Haesook T., Griffin, Gabriel K., Song, Joo Y., Merryman, Reid W., Bedell, Victoria, Pak, Christine, Sun, Heather, Paris, Tanya, Stiller, Tracey, Brown, Jennifer R., Budde, Lihua E., Chan, Wing C., Chen, Robert, Davids, Matthew S., Freedman, Arnold S., Fisher, David C., Jacobsen, Eric D., Jacobson, Caron A., LaCasce, Ann S., Murata-Collins, Joyce, Nademanee, Auayporn P., Palmer, Joycelynne M., Pihan, German A., Pillai, Raju, Popplewell, Leslie, Siddiqi, Tanya, Sohani, Aliyah R., Zain, Jasmine, Rosen, Steven T., Kwak, Larry W., Weinstock, David M., Forman, Stephen J., Weisenburger, Dennis D., Kim, Young, Rodig, Scott J., Krishnan, Amrita, Armand, Philippe · 2017 · Journal of Clinical Oncology

Abstract

Purpose: Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with poor outcomes after standard chemoimmunotherapy. Data are limited regarding outcomes of patients with relapsed or refractory (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT). We retrospectively studied the prognostic impact of DEL and DHL status on ASCT outcomes in patients with rel/ref DLBCL. Methods: Patients with chemotherapy-sensitive rel/ref DLBCL who underwent ASCT at two institutions and in whom archival tumor material was available were enrolled. Immunohistochemistry for MYC, BCL2, and BCL6 and fluorescence in situ hybridization (FISH) for MYC were performed. In cases with MYC rearrangement or copy gain, FISH for BCL2 and BCL6 was also performed. Results: A total of 117 patients were included; 44% had DEL and 10% had DHL. DEL and DHL were associated with inferior progression-free survival (PFS), and DHL was associated with poorer overall survival (OS). The 4-year PFS in patients with DEL compared with those with non-DEL was 48% versus 59% ( P = .049), and the 4-year OS was 56% versus 67% ( P = .10); 4-year PFS in patients with DHL compared with those with non-DHL was 28% versus 57% ( P = .013), and 4-year OS was 25% versus 61% ( P = .002). The few patients with concurrent DEL and DHL had a poor outcome (4-year PFS, 0%). In multivariable models, DEL and DHL were independently associated with inferior PFS, whereas DHL and partial response ( v complete response) at transplant were associated with inferior OS. Conclusion: DEL and DHL are both associated with inferior outcomes after ASCT in patients with rel/ref DLBCL. Although ASCT remains a potentially curative approach, these patients, particularly those with DHL, are a high-risk subset who should be targeted for investigational strategies other than standard ASCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.68.2740

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
Herrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., Merryman, R. W., Bedell, V., Pak, C., Sun, H., Paris, T., Stiller, T., Brown, J. R., Budde, L. E., Chan, W. C., Chen, R., Davids, M. S., Freedman, A. S., Fisher, D. C., Jacobsen, E. D., Jacobson, C. A., LaCasce, A. S., Murata-Collins, J., Nademanee, A. P., Palmer, J. M., Pihan, G. A., Pillai, R., Popplewell, L., Siddiqi, T., Sohani, A. R., Zain, J., Rosen, S. T., Kwak, L. W., Weinstock, D. M., Forman, S. J., Weisenburger, D. D., Kim, Y., Rodig, S. J., Krishnan, A., & Armand, P.
Venue
Journal of Clinical Oncology
Published
2017-01-01
Volume
35
Issue
1
Pages
24-31
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2532606512
Cited by
185
References
0
FWCI
14.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. https://app.cochat.ai/papers/10.1200/jco.2016.68.2740
The paper
Herrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., Merryman, R. W., Bedell, V., Pak, C., Sun, H., Paris, T., Stiller, T., Brown, J. R., Budde, L. E., Chan, W. C., Chen, R., Davids, M. S., Freedman, A. S., Fisher, D. C., . . . Armand, P. (2017). Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.68.2740

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.